AstraZeneca hunting more deals

AstraZeneca is seeking more deals to fill its sparse drug pipeline, but it is not in the market for the kind of large acquisition some investors have speculated about. Martin Mackay, head of research, said he was considering smaller acquisitions, product licensing deals and more partnerships with industry peers.